T5371
|
|
|
Others
Ferroptosis
|
L-Buthionine-(S,R)-sulfoximine 是一种细胞渗透性和不可逆的 γ-谷氨酰半胱氨酸合成酶抑制剂,通过消耗 GSH 诱导细胞中的氧化应激,可降低细胞内谷胱甘肽的水平,其对黑色素瘤、乳腺卵巢癌标本的 IC50值分别为1.9 μM、8.6 μM 和29 μM。 |
T7708
|
|
|
Others
Ferroptosis
|
DL-Buthionine-(S,R)-sulfoximine (Butionine sulfoximine) 是 γ-谷氨酰半胱氨酸合成酶的抑制剂,用于治疗实体瘤。 |
T31899
|
|
|
|
FY26 is a potent Os(II) anticancer drug candidate, exerts its activity by generating reactive oxygen species and disrupting the redox balance in cancer cells Coadministration of FY26 and nontoxic doses of L-BSO allows the potentiation of its anticancer ac |
T37248
|
|
|
|
Pantothenate Kinase Inhibitor (PANKi) is a reversible inhibitor of pantothenate kinase (PanK; IC50s = 70, 92, and 25 nM for PanK1β, PanK2, and PanK3, respectively), the rate-limiting enzyme in the synthesis of coenzyme A .1It binds to the ATP-PanK3 complex with an apparent binding constant of 300 nM and exhibits mixed-type inhibition with respect to ATP and pantothenate. PANKi inhibits CoA biosynthesis in C3A cells (IC50= 0.9 μM) with no effect on cell viability when used at concentrations up to 8 μM. PANKi (5 μM) synergizes with BSO to induce ferroptosis in PANC-1 cells and sensitizes the cells to imidazole ketone erastin-induced ferroptosis.2
1.Sharma, L.K., Leonardi, R., Lin, W., et al.A high-throughput screen reveals new small-molecule activators and inhibitors of pantothenate kinasesJ. Med. Chem.58(3)1563-1568(2015) 2.Badgley, M.A., Kremer, D.M., Maurer, H.C., et al.Cysteine depletion induces pancreatic tumor ferroptosis in miceScience368(6486)85-89(2020) |